{
    "url_original": "https://www.wsj.com/articles/in-a-bad-year-for-biotech-stocks-deals-and-vaccines-were-winners-11639564381?mod=markets_lead_pos1",
    "url": "in-a-bad-year-for-biotech-stocks-deals-and-vaccines-were-winners-11639564381",
    "title": "In a Bad Year for Biotech Stocks, Deals and Vaccines Were Winners",
    "sub_head": "Analysts expect cash-rich pharma companies to keep buying and vaccine demand to stay high",
    "category_1": "Markets",
    "category_2": "Stocks",
    "image_1_url": "https://images.wsj.net/im-451826?width=860&height=573",
    "image_1": "im-451826.jpg",
    "time": "2021-12-15 05:33:00",
    "body": "Biotech stocks have crumbled this year and a number of prominent hedge funds have suffered deep losses.<br />But some biotech investors are thriving by focusing on mergers, short selling and Covid-19 stocks. Some analysts and investors say these three strategies will prove successful for biotech investors once again in 2022."
}